home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Interfering With HIV

 
  July, 26 2005 11:30
your information resource in human molecular genetics
 
     
Scientists have found a molecule that interferes with the formation of infectious Human immunodeficiency virus (HIV) particles. The findings, reported in two papers in the August issue of Nature Structural & Molecular Biology could lead to the development of a new class of HIV drugs that slow or prevent the progression of HIV in individuals.

More than 40 million people globally are currently infected with HIV, the causative agent of AIDS, and approximately 5 million people become infected each year. The current treatment for HIV infection involves a combination of drugs that interfere with the activity of proteins crucial for the production of new HIV particles and those that block the entry of the virus into the cell. While the combination therapy has been highly successful, the emergence of HIV strains resistant to more than one of these drugs has made the identification of alternative targets a high priority.

HIV-1 is released from the infected cell as an immature, noninfectious particle with a protein shell composed of Gag proteins. Formation of the infectious particle requires the cleavage of Gag into smaller proteins. One of these smaller proteins, called capsid, must interact with other capsid proteins to form the mature, infectious virus. Now, Hans-Georg Kräusslich and colleagues identify a 12 amino acid peptide that binds to capsid and prevents its interactions with other capsid proteins.

In an accompanying paper, Felix Rey and colleagues show in three-dimensional detail how the peptide interferes with capsid-capsid interactions.

These studies identify the first inhibitor directed against the transformation of immature HIV-1 into infectious particles, which can be developed for antiviral treatment. Furthermore, these studies identify the immature virus particle as a new target for drug design.

Author contacts:

Hans-Georg Kräusslich (Hygiene-Institut, Heidelberg, Germany)
E-mail: Hans-Georg.Kraeusslich@med.uni-heidelberg.de

Felix Rey (CNRS, Gif-sur-Yvette, France)
E-mail: rey@vms.cnrs-gif.fr

Additional contact for comment on papers:

Volker M. Vogt (Cornell University, Ithaca, NY, USA)
E-mail: vmv1@cornell.edu

Also published online: Rey study, and Kräusslich study.

(C) Nature Structural & Molecular Biology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.